Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). (Q44590396)

From Wikidata

Jump to navigation Jump to search

scientific article published in October 2003

Language	Label	Description	Also known as
English	Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy).	scientific article published in October 2003

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

0 references

Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Neil Easton

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Jeff Fry

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Esther O'Shea

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Adam Watkins

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Shaun Kingston

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Charles A Marsden

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

0 references

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

987

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

144-154

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Amphetamine designer drugs - an overview and epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

5‐HT loss in rat brain following 3, 4‐methylenedioxymethamphetamine (MDMA), p‐chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine but not by 2-hydroxy-4,5-methylenedioxymethamphetamine or 2-hydroxy-4,5-methylenedioxyamphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Orally administered MDMA causes a long-term depletion of serotonin in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

The nature of halogen substitution determines the mode of cytotoxicity of halopropanols

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

In vivo formation of aromatic hydroxylated metabolites of 3,4-(methylenedioxy)methamphetamine in the rat: Identification by ion trap tandem mass spectrometric (MS/MS and MS/MS/MS) techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Ion trap tandem mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy)methamphetamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Major metabolites of(±)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Metabolism of 5-(glutathion-S-yl)-alpha-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Serotonergic neurotoxicity of methylenedioxyamphetamine and methylenedioxymetamphetamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy').

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA)

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Transformation of dopamine and alpha-methyldopamine by NG108-15 cells: formation of thiol adducts.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites by gas chromatography/mass spectrometry.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6)

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

The neurochemical and stimulatory effects of putative metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2903319-5

7 January 2021

Identifiers

10.1016/S0006-8993(03)03319-5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44590396&oldid=1372524378"